Scarica l'app Stockscreener
16.70
0.42%
-0.10
Dopo l'orario di chiusura:
16.70
Neurogene Inc Borsa (NGNE) Ultime notizie
Rhumbline Advisers Buys 1,326 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401 - Seeking Alpha
Neurogene (NASDAQ:NGNE) Shares Down 8.4% – Here’s Why - Defense World
Neoleukin Therapeutics, Inc. Announces Reduction in the Workforce -March 08, 2023 at 05:00 pm EST - Marketscreener.com
Neurogene to Participate in Upcoming Conferences - Business Wire
Can These 3 Healthcare Conferences Reveal Neurogene's Next Big Move? - StockTitan
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - Yahoo Canada Finance
Neurogene (NGNE) to Release Quarterly Earnings on Monday - Defense World
Neurogene (NGNE) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neurogene Inc (NGNE) Shares Decline Despite Market Challenges - The News Heater
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - accessnewswire.com
Should You Expect Neurogene Inc (NASDAQ:NGNE) To Recover From Its 38.11% Gain From Highs? - Marketing Sentinel
Get in on Neurogene Inc’s (NGNE) buy-in window today! - SETE News
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - Victoria Advocate
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Shareholders that Lost Money on Neurogene Inc. (NGNE) Should Contact Levi & Korsinsky About Securities Fraud InvestigationNGNE - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Barclays PLC Purchases 11,316 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Progress in Rett Syndrome Program - TipRanks
Jane Street Group LLC Invests $324,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $60.83 Average PT from Analysts - MarketBeat
7,050 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Franklin Resources Inc. - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Sells 1,463 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Acquires 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Buys 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Charles Schwab Investment Management Inc. Buys 741 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
MetLife Investment Management LLC Invests $254,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):